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Polyhydroxyalkanoates (PHAs) are biopolyesters synthesized as small spherical 
cytoplasmic inclusion bodies by a range of bacteria. Recently, PHA beads have been 
investigated for use as a vaccine delivery platform by using engineered heterologous 
production hosts that allowed the efficient display of vaccine candidate antigens on the 
beads surface and were found to greatly improve immunogenicity of the displayed 
antigens. However, like other subunit vaccines, these antigen-displaying (vaccine) PHA 
beads only provide a limited repertoire of antigens. 
  
In this thesis we investigate the idea of directly utilizing the disease causative pathogen 
or model organism to produce vaccine PHA beads with a large antigenic repertoire. 
These beads are hypothesized to have the potential to induce greater protective 
immunity compared to production of the same PHA bead in a heterologous production 
host.  
 
This concept was exemplified with Pseudomonas aeruginosa and Mycobacterium 
tuberculosis as model human pathogens. For P. aeruginosa we describe the engineering 
of this bacterium to promote PHA and Psl (polysaccharide) production. This represents 
a new mode of functional display for the engineering, production, and validation of a 
novel OprI/F-AlgE fusion antigen-displayed on PHA beads. For the disease tuberculosis 
we investigated the use of nonpathogenic M. smegmatis as a model organism for M. 
tuberculosis. We described the bioengineering, production, and validation of Ag85A-
ESAT-6 displayed on PHA beads produced in M. smegmatis.  
 
Here we showed that both organisms were harnessed to produce custom-made PHA 
beads for use as particulate subunit vaccines that carried copurifying pathogen-derived 
proteins as a large antigenic repertoire and the ability of these vaccine PHA beads to 
generate a protective immune response.  
  
This novel bioengineering concept of particulate subunit vaccine production could be 
applied to a range of pathogens naturally producing PHA inclusions for developing 
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